home / stock / crdl:cc / crdl:cc news

CRDL:CC News and Press, Cardiol Therapeutics Inc.

Stock Information
Company Name: Cardiol Therapeutics Inc.
Stock Symbol: CRDL:CC
Market: TSXC
Website: cardiolrx.com
Menu
CRDL:CC CRDL:CC Quote CRDL:CC Short CRDL:CC News CRDL:CC Articles CRDL:CC Message Board
Get CRDL:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
CRDL:CC - Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased ...
CRDL:CC - Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL) (TSX: CRDL ) (" Cardiol " or the " Company "), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today annou...

CRDL:CC - Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announ...

CRDL:CC - Top Canadian Stocks to Buy Right Away With $5,000

2026-01-21 16:40:00 ET Canadian investors looking to beat broader market returns should identify a portfolio of companies across sectors that are growing steadily. In this article, I have identified three top Canadian stocks to buy right now with $5,000. Let’s see why. ...
CRDL:CC - Cardiol Therapeutics announces $13.5M bought-deal private placement

2026-01-16 08:57:00 ET More on Cardiol Therapeutics Inc. Seeking Alpha’s Quant Rating on Cardiol Therapeutics Inc. Historical earnings data for Cardiol Therapeutics Inc. Financial information for Cardiol Therapeutics Inc. Read the full article on See...

CRDL:CC - Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announ...

CRDL:CC - Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announ...
CRDL:CC - Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients. Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum. Full enrollment expected in...

CRDL:CC - New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis. Results provide clinical evidence that CardiolRx™ reduces inflamma...

CRDL:CC - Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market. This allowance fortifie...
Next 10